Description du projet
Nouveaux médicaments intranasaux contre le SRAS-CoV-2
L’ampleur de la pandémie actuelle de COVID-19 exige des efforts concertés pour trouver des diagnostics, des thérapies et des vaccins efficaces. Dans ce but, le projet Fight-nCoV, financé par l’UE, accélérera le développement préclinique de nouveaux antiviraux à large spectre administrés par inhalation. Les travaux s’appuient sur la recherche en cours sur les médicaments qui bloquent les entrées virales et testeront leur innocuité et leur activité contre le SRAS-CoV-2 dans un modèle macaque de la maladie. Les informations sur l’efficacité de ces inhibiteurs intranasaux chez les primates non humains jetteront les bases de la prochaine étape du développement de ces médicaments à usage humain.
Objectif
Project coordinator: Professor Anna-Lena Spetz, MD, PhD, Stockholm University, Sweden
Objectives of proposal: Our consortium “Fight-nCoV” will accelerate preclinical development of new broad-spectrum antivirals for inhalation, building on breath-taking ongoing research. We will determine and characterize the antiviral activity and safety of three viral entry inhibitors (oligonucleotide, Macro-I, tweezer) against SARS-CoV-2 in vitro and in vivo. To enable this, we will build capacity for evaluation of antiviral efficacy against SARS-CoV-2 in vitro using viral pseudotypes and wild-type SARS-CoV-2 as well as in vivo in non-human primates. Safety studies will be performed according to OECD GLP guidelines.
Expected results: We will establish a SARS-CoV-2 spike pseudotype system allowing a standardized high throughput evaluation of the antiviral activity of candidate drugs. We will have determined the antiviral efficacy of three novel broad-spectrum viral entry inhibitors: oligonucleotide, macromolecular polymers, and molecular tweezers. We will also build capacity for innovation and preclinical evaluation of our broad-spectrum antivirals and vaccines against SARS-CoV-2 by establishing a macaque challenge model. “Fight-nCoV” will provide efficacy data of our drug candidates given intranasally in non-human primates challenged with SARS-CoV-2, enable an early and valuable outcome for stakeholders and the civil society.
Timeline of proposal: Ongoing-30 months
Key partners: Roger Le Grand, Director animal facility, CEA, France; Urban Höglund, CEO Adlego Biomedical, Sweden; Jan Münch, Professor in Molecular Virology, UULM, Germany; Alexander Zelikin, Associate Professor, formulation expert, AU, Denmark; and Thomas Schrader, Professor of Chemistry, UDE, Germany.
Champ scientifique
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
10691 Stockholm
Suède